about
Asthma in pregnancy and its pharmacologic treatmentUse of a job-exposure matrix to assess occupational exposures in relation to birth defectsNonsteroidal antiinflammatory drugs in late pregnancy and persistent pulmonary hypertension of the newbornMaternal medication use and risks of gastroschisis and small intestinal atresiaAsthma morbidity after the short-term use of ibuprofen in childrenIdentification of phthalates in medications and dietary supplement formulations in the United States and CanadaRisks and safety of pandemic H1N1 influenza vaccine in pregnancy: exposure prevalence, preterm delivery, and specific birth defects.Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants.Seasonal influenza vaccination during pregnancy and the risks of preterm delivery and small for gestational age birthInfluenza Vaccination Coverage During Pregnancy - Selected Sites, United States, 2005-06 Through 2013-14 Influenza Vaccine Seasons.Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.Signal generation and clarification: use of case-control data.Application of data screening to drug exposure in large risk factor studies of birth defects.Tolerability of oral xylitol solution in young children: implications for otitis media prophylaxis.The use of cisapride in children. The North American Society for Pediatric Gastroenterology and Nutrition.Maternal dietary glycemic intake and the risk of neural tube defectsThe safety of acetaminophen and ibuprofen among children younger than two years old.Folic acid antagonists during pregnancy and the risk of birth defects.Medication use in pregnancy in relation to the risk of isolated clubfoot in offspringAssessment of antihistamine use in early pregnancy and birth defectsMaternal genitourinary infections and the risk of gastroschisis.Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot.Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.Characteristics of persistent diarrhea in a community-based cohort of young US children.First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.Increasing use of ADHD medications in pregnancyMedications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.Periconceptional use of opioids and the risk of neural tube defects.Predictors of recall certainty of dates of analgesic medication use in pregnancy.Maternal dietary glycaemic intake during pregnancy and the risk of birth defectsCase-control studies for identifying novel teratogens.Use of topiramate in pregnancy and risk of oral clefts.Correcting for exposure misclassification using survival analysis with a time-varying exposure.Safety of macrolides during pregnancy.Application of pharmacogenomic strategies to the study of drug-induced birth defects.Folic acid intake and spina bifida in the era of dietary folic acid fortification.Use of antiepileptic medications in pregnancy in relation to risks of birth defectsAntiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007.Association of Clomiphene and Assisted Reproductive Technologies With the Risk of Neural Tube Defects.Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.
P50
Q24633071-A6DF4E95-FB12-4B1D-ABDE-1D354EB827DCQ26340715-8B4C8FBB-FC6D-44E4-9036-352A49B37BA5Q27026121-38EB0A21-E43A-44EB-8755-62F40C0F9604Q28192006-16DA28CF-DE70-4727-83DD-B92CB50FF4EEQ28192296-5B63BDC4-E051-49BE-B4FF-0633CCE73312Q28397343-105B779A-E04E-452B-BA01-4A809E771BA5Q30353447-47923D2C-FC82-4582-B57B-7B6EF50A543EQ30353450-E4818E64-3E49-4552-AFF3-A3D466A0AE9DQ30367964-EAE340CD-13B8-40ED-83E5-108F30162D3AQ30396193-31CEEAC9-EE5A-4EEC-9F75-B5FD6D911F6BQ30399883-4369487B-69AD-422A-A891-17F471F4A57BQ30658394-F4F5349A-9EA4-4721-B05D-1322774EF7E3Q30986274-39556E5E-C5F6-4105-A560-9E4994FF862CQ33436195-7D502AA8-2D09-448C-8C7D-912B3898DADCQ33635615-7AB24C2B-8519-4FBF-9B04-85BAEFD1E464Q33741421-C470DD15-A645-4B63-A422-94190A75D546Q33875714-8102B5CB-3057-40FF-A998-671A29E7D3B3Q33926560-0CFA2219-C633-4658-9EDA-6D776F86A741Q34048103-DDBF556F-8694-481B-8EB0-83CFDD7B40F0Q34075092-E883A104-CB25-4A90-B904-4835874000BAQ34083074-74DB584D-7CDA-4964-B8F0-9185804A0B38Q34270366-AD45BF5E-7AF6-43FE-9D56-119385548EAFQ34492967-AF8E9E77-86C2-4138-8D0D-949660409BDDQ34544454-7EEBEA41-18E2-4254-87D2-927E39641D62Q34642517-DA43AC13-0B4C-4B24-A02A-0636A9EFD188Q35037287-48A991ED-35D1-4626-96B4-0F7057D174A6Q35820722-191306DA-EB25-464A-8E4C-BBDCD9F92CA8Q36019888-BBD92AC4-3623-41D7-ACE3-9F82D7BF0F0BQ36237479-5860992C-7655-4C2E-ABD7-B7BC41927E4CQ36327010-CEF14855-9DC6-40D6-8ECA-A65A6FCF2B85Q36353128-CA6F53BE-6E76-4C09-A14E-7FF085704014Q36356810-7C637B4B-256E-4E01-8597-19ADB3492818Q36374089-0754196A-3F6A-4EC3-8400-BA23A8AD4F7CQ36636707-673A47AD-08DE-4D56-914C-6369236ACBDFQ36741998-F25041CA-AAB4-4560-9948-59CD689D07CDQ36743925-2C7EF75B-2098-45A7-8E00-B0832375E2FEQ36751405-1B37990F-7342-41FA-9ADF-67C4EA673BDFQ36950122-0C0B2920-5224-4B1F-A0C8-C0F02D643A0DQ36952737-7D355284-0563-43E6-B4F2-340F3C5AB5FEQ37020820-4132547B-272D-4231-ADD7-97FD66E504CB
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Allen A Mitchell
@ast
Allen A Mitchell
@en
Allen A Mitchell
@es
Allen A Mitchell
@fr
Allen A Mitchell
@nl
Allen A Mitchell
@sl
type
label
Allen A Mitchell
@ast
Allen A Mitchell
@en
Allen A Mitchell
@es
Allen A Mitchell
@fr
Allen A Mitchell
@nl
Allen A Mitchell
@sl
prefLabel
Allen A Mitchell
@ast
Allen A Mitchell
@en
Allen A Mitchell
@es
Allen A Mitchell
@fr
Allen A Mitchell
@nl
Allen A Mitchell
@sl
P106
P21
P31
P496
0000-0003-0950-6799